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Antiseizure medications (ASMs) are frequently implicated in T cell-mediated drug
hypersensitivity reactions and cause skin tropic pathologies that range in severity from
mild rashes to life-threatening systemic syndromes. During the acute stages of the more
severe manifestations of these reactions, drug responsive proinflammatory CD8+ T cells
display classical features of Th1 cytokine production (e.g. IFNg) and cytolysis (e.g. granzyme
B, perforin). These T cells may be found locally at the site of pathology (e.g. blister cells/fluid),
as well as systemically (e.g. blood, organs). What is less understood are the long-lived
immunological effects of the memory T cell pool following T cell-mediated drug
hypersensitivity reactions. In this study, we examine the ASM carbamazepine (CBZ) and
the CBZ-reactive memory T cell pool in patients who have a history of either Stevens-
Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) from 3-to-20 years following
their initial adverse reaction. We show that in vitro drug restimulation of CBZ-reactive CD8+ T
cells results in a proinflammatory profile and produces a mainly focused, yet private, T cell
receptor (TCR) usage amongst human leukocyte antigen (HLA)-B*15:02-positive SJS or
TEN patients. Additionally, we show that expression of these CBZ-reactive TCRs in a
reporter cell line, lacking endogenous abTCR, recapitulates the features of TCR activation
reported for ASM-treated T cell lines/clones, providing a useful tool for further functional
validations. Finally, we conduct a comprehensive evaluation of the HLA-B*15:02org April 2021 | Volume 12 | Article 6537101
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Frontiers in Immunology | www.frontiersin.immunopeptidome following ASM (or a metabolite) treatment of a HLA-B*15:02-positive B-
lymphoblastoid cell line (C1R.B*15:02) and minor perturbation of the peptide repertoire.
Collectively, this study shows that the CBZ-reactive T cells characterized require both the
drug and HLA-B*15:02 for activation and that reactivation of memory T cells from blood
results in a focused private TCR profile in patients with resolved disease.Keywords: T cells, SJS, Stevens-Johnson syndrome, carbamazepine, drug hypersensitivity, immunopeptidomics,
T cell receptorINTRODUCTION
Antiseizure medications (ASMs) are routinely used to treat
epilepsy and other neuropsychiatric conditions, such as
neuropathic pain and bipolar affective disorder. Commonly
prescribed ASMs, including carbamazepine (CBZ) and
phenytoin (PHT), have been implicated in life-threatening
drug hypersensitivity reactions (DHRs) that predominantly
target the skin (1). These drug reactions typically occur in the
first 2-3 months of drug administration and span a range of
clinical pathologies, including mild rash [e.g. maculopapular
exanthema (MPE)], systemic symptoms [e.g. drug reaction
with eosinophilia and systemic symptoms (DRESS)], as well as
more severe bullous reactions involving rapid development of
blisters and lesions accompanied by skin detachment [e.g.
Stevens-Johnson syndrome (SJS) and toxic epidermal
necrolysis (TEN)] (2–5). Whilst early drug withdrawal can
ameliorate symptoms in milder cases, the more severe
cutaneous reactions require specific clinical treatments and
hospitalization for disease resolution.
ASMs can be segregated into two main groups, aromatic and
non-aromatic compounds. Reports have shown that aromatic
compounds [e.g. CBZ, oxcarbazepine (OXC; a structural
derivative of CBZ), PHT, lamotrigine, phenobarbital] are highly
associated with cutaneous DHRs (1) in individuals of particular
ethnicities driven by their human leukocyte antigen (HLA) genetic
profile. In contrast, the non-aromatic ASMs (e.g. valproic acid,
gabapentin) are considerably less associated with DHRs
[extensively reviewed in (6)]. The greatest risk association
reported for CBZ-induced SJS/TEN is expression of HLA-
B*15:02 in individuals of Han Chinese descent (Odds Ratio 895)
(7), as well as other Asian ethnicities including Thai, Malaysian
and Indian (8–10). Indeed, carriers of the broad HLA-B75
serotype (includes B*15:02, B*15:08, B*15:11, B*15:21) are also
adversely affected by CBZ treatment (8, 10–14). HLA-A allotype
risk associations for HLA-A*31:01, -A*24:02 and -B*57:01 have
also been reported for CBZ-induced SJS/TEN, DRESS and MPE
across different ethnicities (Han Chinese, Korean, European,
Japanese) (13, 15–20), with lower risk associations.ll; ASM, antiseizure medication; CBZ,
eosinophilia and systemic symptoms;
A, human leukocyte antigen; MPE,
receptor; PBMC, peripheral blood
hnson syndrome; TEN, tox ic
org 2Small molecule drugs, such as ASMs, can promote immune
reactions via T cell activation. ASM-induced T cell activation is
proposed to occur via non-covalent and labile interactions
between the drug, or a metabolite of the parent drug, and the
HLA/peptide complex and T cell receptor (TCR) (21).
Additionally, whilst peptide occupancy of the HLA molecule is
necessary, there is no requirement for de novo peptide/HLA
complex formation (21) and the drug does not markedly alter the
anchor residue preference of HLA-B*15:02 suggesting it is not
binding within the primary anchor pockets during peptide
loading (22). Contesting the latter, a recent report has
suggested that the CBZ metabolite, carbamazepine-10,11-
epoxide (ECBZ), is capable of altering the HLA-B*15:02
immunopeptidome and anchor residue prevalence (23). To
date there is no published structure of the interaction of CBZ
and the peptide/HLA and/or TCR, although diverse in silico
models have been generated ranging from our previous
proposal of occupation of the antigen-binding cleft, to more
surface exposed positions, or, with the additional inclusion
of identified drug-reactive TCRs, the HLA-TCR interface
(21, 22, 24).
In contrast to the antiretroviral drug abacavir, which
drastically alters the immunopeptidome and facilitates a
diverse and polyclonal T cell response (25–27), examination of
CBZ-induced T cells revealed a much more focused TCR usage
associated with SJS/TEN (28). A recent study utilized next
generation sequencing to examine the blister cells of CBZ-
induced SJS/TEN patients identifying a public HLA-B*15:02-
restricted abTCR [complementarity determining region (CDR)3
sequence; TCRa VFDNTDKLI and TCRb ASSLAGELF] that
also recognized structural analogs of CBZ (24). These TCR
signatures contrast with an early report demonstrating the
expansion of VA-22 and VB-11-ISGSY dominant clonotypes
derived from the blister fluid of SJS/TEN patients recruited in
Taiwan expressing HLA-B*15:02 (28). These TCRs were
identified using traditional Sanger sequencing and were
confounded by in vitro T cell co-culture with antigen
presenting cells (APCs), which has been suggested to bias the
outgrown T cell repertoire (29). Another study examining the ex
vivo TCRb repertoire in peripheral blood mononuclear cells
(PBMCs) isolated from CBZ-induced SJS (n=5) or TEN (n=1)
patients showed that diversity was directly linked to disease
severity, with the TEN patient having a significantly decreased
TCRb repertoire compared to SJS patients (30).
What is less understood are the long-lived immunological
features of the CBZ-responsive memory T cell pool in patientsApril 2021 | Volume 12 | Article 653710
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immunological profiles to those reported during active disease,
such as effector functions including Th1 cytokine production
(e.g. IFNg) (28) and cytolytic molecules (e.g. granzyme B,
perforin) (31), TCR repertoire clonality, mode of drug
recognition and cross-reactivity towards other ASMs? This
study shows that the in vitro drug expanded TCR repertoire of
resolved CBZ-induced SJS or TEN patients remains relatively
clonal years after acute disease. These T cells respond to HLA-
B15-positive APCs in the presence of CBZ, as well as related
compounds, a finding that is recapitulated by expression of these
cloned TCRs in a reporter cell line. Here, the responses required
the continuous presence of soluble drug and HLA-B15
expression, without the need for de novo generation of the
peptide/HLA complex. No marked drug-induced alteration in
peptide anchor preference of HLA-B*15:02 was induced by any
of CBZ, the metabolite ECBZ, or the structurally related ASM
OXC. Together these data support the presence of a long-lived
memory pool of CBZ responsive T cells in SJS or TEN patients,
which are activated by structurally related ASMs in the absence
of marked alteration of the immunopeptidome.MATERIALS AND METHODS
Study Cohort
Eight patients were recruited from Hong Kong, with six HLA-
B*15:02-positive patients experiencing CBZ-induced SJS or TEN,
one HLA-B*15:02-negative patient with CBZ-induced SJS and
one CBZ-tolerant (Table 1, Supplementary Table 1). As
described in our previous studies (32, 33) the diagnosis of SJS
or TEN was based on the criteria by Roujeau and Stern (2)
defined by skin detachment in two or more mucosal sites, and
was confirmed by dermatologists. Healthy HLA-B*15:02+
individual controls (AP numbers; n=7; Table 1) were also
recruited from both Monash University and the Australian
Bone Marrow Donor Registry. All study participants provided
written consent, with ethics approval granted by the JointFrontiers in Immunology | www.frontiersin.org 3Chinese University of Hong Kong-New Territories East Cluster
Clinical Research Ethics Committee (Hong Kong; CRE-2006.203
for patients), Monash University (Victoria, Australia; HREC-
4717 for healthy individuals) and the Australian Bone Marrow
Donor Registry (New South Wales, Australia; 2013/04 for
healthy individuals).
Cell Preparation and In Vitro Expansion of
Drug-Induced T Cells
Blood samples were collected from study participants, with
PBMCs isolated using Ficoll-Paque (GE Healthcare, Uppsala,
Sweden) density gradient centrifugation and either used
immediately or cryopreserved in fetal calf serum (FCS)
containing 10% DMSO (Sigma-Aldrich, MO, USA) at -196°C
until required. Before use for T cell stimulation, PBMCs were
quickly thawed in 37°C and washed twice in RPMI 1640 (Gibco,
Life Technologies, NY, USA) and resuspended in Complete
Medium [RPMI 1640 supplemented with 2 mM MEM
nonessential amino acid solution (Gibco), 100 mM HEPES
(Gibco), 2 mM L-glutamine (Gibco), Penicillin/Streptomycin
(Gibco), 50 mM 2-mercaptoethanol (Sigma-Aldrich) and
10% heat inactivated human blood group AB serum
(Sigma-Aldrich)].
Drug-induced T cells were in vitro expanded following PBMC
stimulation at a density of 5 million per 2 mL of Complete
Medium in a 24-well plate with 25 mg/mL of either CBZ (Sigma)
or the metabolite ECBZ (Sigma or SYNthesis med chem,
Australia). On days 4 to 14, T cell cultures were supplemented
with 50 U/mL of recombinant human IL-2 (Peprotech, NJ, USA)
and subcultured as required to ensure optimal outgrowth.
Antigen Presenting Cells and
HLA Expression
C1R.B*15:01, C1R.B*15:02, C1R.B*15:21, C1R.B*15:25 and
C1R.B*08:01 transfectants and transductants were generated
from the HLA class I-reduced C1R B-lymphoblastoid cell line,
which has minimal HLA-B*35:03 and normal levels of HLA-
C*04:01 cell surface expression (34, 35). All APCs were culturedTABLE 1 | Study participants: cases and healthy donors.
Participant ID Gender CBZ exposure Reaction HLA-B*15:02 Post-reaction sample
collection (months)
Cases T00016 Female Yes SJS Positive 49
T00024 Female Yes SJS Positive 39
E10056 Female Yes TEN Positive 129
E10076 Male Yes SJS Positive 58
E10314 Male Yes SJS Negative 166
E10367 Female Yes SJS Positive 144
E10630 Female Yes SJS Positive 246
E10493 Female Yes Tolerant Negative N/A
Healthy donors AP005 Unknown No N/A Positive N/A
AP017 Unknown No N/A Positive N/A
AP022 Unknown No N/A Positive N/A
AP026 Unknown No N/A Positive N/A
AP027 Unknown No N/A Positive N/A
AP029 Unknown No N/A Positive N/A
AP102 Female No N/A Positive N/AApril 2021 | VoluN/A, not applicable; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis.me 12 | Article 653710
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heat inactivated FCS (Sigma-Aldrich)]. Maintenance of
transfected HLA expression (except green fluorescent protein
(GFP) tagged C1R.B*15:21 and C1R.B*15:25) during long-term
culture was facilitated by selection antibiotics [Geneticin G418
(0.5 mg/ml; Roche Diagnostics, Mannheim, Germany) or
hygromycin B (0.3 mg/ml; Life Technologies, Carlsbad, CA)]
as required. GFP expression is used as a reporter of HLA
expression facilitating flow cytometric sorting. Increased HLA-
I expression (compared to C1R Parental) was confirmed via flow
cytometry by indirect staining with appropriate antibodies; anti-
human pan HLA-I (W6/32 hybridoma; Supplementary Figure
1A), anti-human HLA-Bw6 (HB152 hybridoma; Supplementary
Figure 1B) and a secondary goat anti-mouse IgG phycoerythrin
(PE) (1:200 dilution; Southern Biotech, Birmingham, AL). All
hybridomas were produced in-house. Stained cells were acquired
on LSRII flow cytometer [Becton Dickinson (BD), San Jose, CA].
Flow cytometry data was analyzed using FlowJo software
(version 10, BD).
Drug-Pulsed APCs and T Cell Stimulation
Functionality of the drug-induced T cells, including cross-
reactivity, was assessed using intracellular cytokine staining
(ICS) for production of either IFNg and/or TNF (36). Briefly,
day 14 T cells (2x105) were restimulated with Dynabeads®
Human T-Activator CD3/CD28 beads (positive control; Life
Technologies), drug alone (25 mg/mL), APC alone (1x105;
APC) or APC in the presence of drug (1x105; APC+25 mg/mL
drug) for a total of six hours. Brefeldin A (10 µg/mL; Sigma-
Aldrich) was added for the last 4 hours of co-culture. Cells were
then surface labeled with LIVE/DEAD® fixable Aqua stain (Life
Technologies), CD4 PE (clone RPA-T4), CD8 PerCP-Cy5.5
(clone SK1), fixed in 1% paraformaldehyde (ProSciTech,
Queensland, Australia) in phosphate buffered saline (PBS) and
then permeabilized with 0.3% Saponin (Sigma-Aldrich)
containing IFNg PE-Cy7 (clone B27) and TNFa V450 (clone
MAb11) before acquisition on a LSRII flow cytometer [Becton
Dickinson (BD), San Jose, CA, USA] (Supplementary Figure
2A). All monoclonal antibodies were purchased from BD and
titrated for optimal staining efficiency. A maximum of 50,000
lymphocytes were acquired on a BD LSRII flow cytometer
utilizing BD FACSDIVA™ software (FlowCore, Monash
University) and analyzed using FlowJo software (version 10,
BD). Representative gating strategy is shown in Supplementary
Figure 2B.
Paired abTCR Analysis of Drug-Induced
T Cells
A single-cell sort was performed to characterize the abTCR
signature of drug-induced T cells using the IFNg Secretion
Assay–Detection Kit (allophycocyanin; Miltenyi Biotec, CA,
USA). Cryopreserved T cell lines were thawed and rested
overnight in Complete Medium. T cell lines (maximum of
5x106 cells) were incubated with either C1R.B*15:02 alone or
C1R.B*15:02 + drug (25 mg/mL) target cells (2:1 ratio) in RH5
media (same constituents as Complete Medium, except 5% heatFrontiers in Immunology | www.frontiersin.org 4inactivated human blood group AB serum) for 4 hours at 37°C,
5% CO2. Cells were washed in cold Wash Buffer (0.5% FCS, 2
mM EDTA pH 8.0 in PBS), centrifuged (285 ×g, 5 min, 4°C) and
supernatant aspirated before addition of IFNg catch reagent
antibody according to manufacturer’s instructions. Cells were
incubated on ice for 5 min and topped up to 10 mL with warm
RH5 media, and drug (25 mg/mL) was re-added. Cells were
incubated for 45 min at 37°C, 5% CO2 with rotation. Cells were
washed in cold Wash Buffer, centrifuged and supernatant
aspirated prior to co-staining with IFNg allophycocyanin
detection reagent and CD8 FITC (clone HIT8a). Cells were
incubated on ice for 20 min, washed in cold Wash Buffer,
centrifuged and resuspended in 300 mL cold Wash Buffer
(Supplementary Figure 2C).
Single cells were sorted on a BD Influx flow cytometer
(FlowCore, Monash University) directly into 96-well PCR
plates (Bio-Rad, Hercules, CA, USA) based on CD8+IFNg- for
drug-unresponsive T cells (negative control) and CD8+IFNg+ for
drug-induced T cells (Supplementary Figure 2C). Sorted plates
were immediately stored at -80°C until required. Analysis of
paired TCRa and b genes was carried out by multiplex nested
RT-PCR and sequencing of a and b products as described
previously (37). Both external and internal rounds of PCR
included 40 TRAV and 27 TRBV forward primers, and a
TRAC and TRBC reverse primer, as detailed elsewhere (37).
Sequences were analyzed according to the ImMunoGeneTics/V-
QUEry and STandardization web-based tool (38). All TCR
nomenclature was according to Folch et al. (39). CDR3 amino
acid sequences described within the text start from CDR3-
position 3, which is equivalent to amino acid position 107 of
the TRAV and TRBV segments, and end at TRAJ-position 10 or
TRBJ-position 6.
Generation of SKW3.TCR Cell Lines
Full-length human TCRa and TCRb cDNA was cloned into
pMIG vector separated by a self-cleaving 2A peptide as described
previously (40, 41). A pMIG vector, with IRES-linked GFP
expression, containing a specific TCR for AP026/CBZ, E10056/
CBZ, or E10630/CBZ (4 mg) was retrovirally transduced into
SKW3.hCD8ab cells (kindly provided by Dr. Zhenjun Chen,
Peter Doherty Institute for Infection and Immunity, University
of Melbourne; hereafter referred to as SKW3), which is negative
for endogenous TCRab but contains CD3 and its signaling
components, using HEK293T packaging cells, pEQ-pam3(-E)
(4 mg) and pVSV-G (2 mg) packaging vectors and Lipofectamine
3000 as previously described (41). The original SKW3 parental
cell line was kindly provided by Dr. Klaus Steube, Leibniz
Institute DSMZ-German Collection of Microorganisms and
Cell Cultures (Braunschweig, Germany). The HLA typing of
SKW3 cells is HLA-A*11:01, 30:01; B*35:01, 44:02; C*04:01,
05:01; DRB1*01:03, 04:01; DQB1*03:01; DPB1*04:01, 04:02. A
non-specific control, SKW3.LC13 cell line, specific for an EBV
epitope FLRGRAYGL (EBNA3A325-333) restricted to HLA-
B*08:01 was generated in our previous study (41). The
SKW3.TCR cell lines were maintained in RF10 media
(Supplementary Figure 1C).April 2021 | Volume 12 | Article 653710
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Activation of SKW3.TCR cells (1x105) was assessed using cell-
surface CD69 upregulation after 17-20 hours incubation with
either C1R Parental, C1R.B*15:01, C1R.B*15:02, C1R.B*15:21,
C1R.B*15:25 or C1R.B*08:01 targets (1:1 ratio) under different
sets of conditions, including either direct drug addition (25 mg/
mL) or by drug-pulsing APC (25 mg/mL) overnight then
thorough washing in RPMI before SKW3.TCR co-incubation.
SKW3.TCR cells were co-stained with CD3 PE-Cy7 (clone SK7),
CD8 PerCP-Cy5.5 (clone SK1), CD69 APC (clone L78), LIVE/
DEAD® fixable Aqua stain. For all experiments, stimulation with
Dynabeads® Human T-Activator CD3/CD28 beads (Life
Technologies) served as a positive control, and SKW3.TCR
cells alone as a negative control. Flow cytometry data were
acquired and analyzed as described previously (41). The CD69
expression profiles were measured as geometric mean
fluorescence intensity (MFI) to provide more meaningful
evaluation of changes in the relative amounts of expressed
protein per cell. A maximum of 50,000 lymphocytes were
acquired on a BD LSRII flow cytometer utilizing BD
FACSDIVA™ software (FlowCore, Monash University) and
analyzed using FlowJo software (version 10, BD).
Immunopeptidome Analysis
The C1R.B*15:02 cell line was in vitro expanded in RF10, and
treatment of cells with either CBZ (Sigma), ECBZ (Sigma or
SYNthesis med chem, Australia) or OXC (SYNthesis med chem)
for peptide elutions was performed at 25 mg/mL for 48 hours in
roller bottles prior to harvesting. Cells (0.9-1.1 x 109) were
pelleted, washed twice in PBS and snap-frozen in liquid
nitrogen. Cells were lysed, and the HLA class I isolated by
immunoaffinity purification using solid-phase bound pan HLA
class I antibody W6/32 as described previously (42). Peptides
were dissociated using 10% acetic acid and separated from the
HLA heavy and light (beta-2 microglobulin; b2m) chains by
Reversed Phase HPLC (RP-HPLC) as described (43), monitoring
elution by 215nm absorbance and collecting 500 mL fractions.
The retention times of CBZ, ECBZ and OXC were determined
through subjecting each molecule to the same RP-HPLC
protocol. Peptide containing fractions, avoiding regions
containing b2m and heavy chain, were vacuum concentrated
and concatenated to generate 13 pools, including 3 pools aligned
with the retention times of CBZ (pool 10), ECBZ (pool 12) and
OXC (pool 13). Pools were vacuum concentrated to remove
residual acetonitrile (ACN) and reconstituted in 15 mL 2% ACN,
0.1% formic acid (FA), spiked with 250 fmol iRT peptides (44).
Pools were analyzed by liquid chromatography-tandem mass
spectrometry (LC-MS/MS) using a data dependent acquisition
(DDA) strategy on a Q-Exactive Plus Hybrid Quadrupole
Orbitrap (Thermo Fisher Scientific) utilizing a Dionex
UltiMate 3000 RSLCnano system (Thermo Fisher Scientific).
5-6 µL of concentrated material was loaded onto an Acclaim
PepMap 100 (100 µm x 2 cm, nanoViper, C18, 5 µm, 100Å;
Thermo Scientific) in 2% ACN, 0.1% FA at a flow rate of
15 µL/min. Peptides were separated over an Acclaim PepMap
RSLC (75 µm x 50 cm, nanoViper, C18, 2 µm, 100Å; ThermoFrontiers in Immunology | www.frontiersin.org 5Scientific) at 250 nL/min using a gradient of Buffer A (0.1% FA)
and Buffer B (80% ACN, 0.1% FA) as follows: 2.5-7.5% B in 1
min, 7.5-32.5% B in 55 min, 32.5-40% B in 5 min, 40-99% B in 5
min, 99% B for 6 minutes, and 99-2.5% B in 1 min, prior to re-
equilibration at 2.5% B for 20 min. Data were collected in
positive mode: MS1 resolution 70,000, scan range 375-2000 m/
z; MS2 resolution 17500, scan range 200-2000 m/z. The top 12
ions of +2 to +5 charge per cycle were chosen for MS/MS with a
dynamic exclusion of 15 seconds.
Peptide sequences were assigned using PEAKS X+
(Bioinformatics Solutions Inc.) via a database search against
the reviewed human proteome (UniProt/Swiss-Prot, accessed
October 2018), and a database of common contaminants. The
following settings were employed: Instrument – OrbiTrap (Orbi-
Orbi), Fragment – HCD, Acquisition - DDA, Parent Mass Error
Tolerance - 20.0 ppm, Fragment Mass Error Tolerance - 0.02 Da,
Precursor Mass Search Type - monoisotopic, Enzyme - None,
Variable Modifications - Oxidation (M) 15.99, Deamidation
(NQ) 0.98, and Cysteinylation: 119.00, Max Variable PTM Per
Peptide - 3. Peptides assigned at a 5% peptide false discovery rate
(FDR) were utilized in downstream analyses. DDA data from
previous analyses of the immunopeptidome of endogenous HLA
I and II of C1R cells (43) were searched separately via the same
pipeline as control datasets.
To characterize the HLA-B*15:02 binding motif, peptide
sequences identified at a 5% peptide FDR in control data sets
representing the endogenous HLA class I and II of C1R cells were
removed. So too were peptides assigned without a protein
accession or mapping exclusively to proteins in the
contaminant database. For peptide counts, motif and length
distribution analysis, only 7-20mer peptides were considered
and peptides sequences containing deamidations or
cysteinylations were treated as distinct from the native
sequence. Figures were generated using Prism 9.0, GraphPad
software (San Diego, CA). The mass spectrometry proteomics
data have been deposited to the ProteomeXchange Consortium




Drugs/metabolites were detected using a targeted LC-multiple
reaction monitoring-MS (LC-MRM-MS) approach on a SCIEX
QTRAP® 6500 plus mass spectrometer, coupled to an Ekspert™
nanoLC 415. For pools aligned with the RP-HPLC retention time
of CBZ (pool 10), ECBZ (pool 12) and OXC (pool 13), residual
sample post-peptide analysis was diluted by a factor of ~2. 6 mL
diluted sample was loaded onto a NanoLC Trap ChromXP C18
column (350 mm x 0.5 mm, 3 µm particle size, 120 Å pore size) in
2% ACN, 0.1% FA at a flow rate of 5 µL/min for 5 minutes, prior
to separation over a ChromXP nanoLC C18 column (75 µm x 15
cm, 3 µm particle size, 120 Å pore size) at 300 nL/min using an
increasing gradient of Buffer B (80% ACN, 0.1% FA): 0–1 min
2% B, 1-2 min 2–12% B, 2–30 min 12–35% B, 30–50 min 35–80%
B, 50–54 min hold at 80% B, 54-55 min 80-2% B, 55-65 min re-
equilibration at 2% B. The QTRAP® 6500 was operated inApril 2021 | Volume 12 | Article 653710
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For detection of CBZ three transitions were set with a Q1 mass of
237.102, and Q3 masses of 192.082 [Collision Energy (CE) 30],
194.097 (CE 25) and 220.077 (CE 15). For ECBZ and OXC, five
transitions were set with a Q1 mass of 253.097, and Q3 masses of
180.082 (CE 30), 182.096 (CE 25), 208.076 (CE 30), 210.092 (CE
25) and 236.071 (CE 25). CE values were optimized based on
injection of solubilized drug/metabolite. Three transitions for
each iRT peptide were also monitored. Drug peaks areas are the
sum peak areas of the monitored transitions. Drug peak areas
were normalized to the sum peak areas of iRT peptides B-G
(GAGSSEPVTGLDAK, VEATFGVDESNAK, YILAGVENSK,
TPVISGGPYEYR, TPVITGAPYEYR, DGLDAASYYAPVR).
Figures were generated using Prism 9.0, GraphPad software.
Statistical Analysis
All data were reported as mean ± standard error of the mean
(SEM), unless stated otherwise. Statistical significance was
determined by nonparametric one-way ANOVA with post-hoc
Tukey’s multiple comparison test, Mann-Whitney test or
multiple comparisons using Holm-Sidak method (Prism 8.0,
GraphPad software) with *p<0.05, **p<0.005 and ****p<0.0001.
Standard error of the difference between mean amino acid
prevalence was calculated using the Welch t-test (Prism 9.0,
GraphPad software).RESULTS
Drug-Induced Recall Responses Are
Restricted to CD8+ T Cells in Recovered
SJS or TEN Patients
We examined the immune reactivity profiles of convalescent SJS
or TEN patients (7 cases and one drug-tolerant case) to
determine whether they maintain a memory pool of T cells
specific to the culprit drug that can be reactivated following
subsequent drug exposures (Table 1). PBMCs treated with 25
mg/mL CBZ were expanded in vitro for 14 days. Outgrown CBZ-
induced T cell lines were then restimulated in a 6-hour ICS assay
with either no drug (untreated), CBZ (25 mg/mL), or with HLA-
B*15:02+ APCs C1R.B*15:02 or C1R.B*15:02+CBZ (25 mg/mL)
to measure activation via production of Th1 cytokines (IFNg and
TNF). Group data of the recovered patients showed that the
CBZ-reactive T cell response, where activation was observed
following CBZ and APC+CBZ stimulation, was primarily
restricted to CD8+ T cells. However, the CD4+ T cells did
show immune recognition of CBZ alone, likely via the
mechanism of self-T cell presentation (i.e. T-T presentation).
Here, 6 out of 7 patients expressing HLA-B*15:02 demonstrated
non-specific CD4+ T cell responses towards the APCs most likely
due to HLA class II mismatches expressed by the C1R.B*15:02
transfectant (Figure 1A). Optimization experiments, using
healthy donors, showed similar CD4+ T cell immune responses
(i.e. production of Th1 cytokines IFNg and TNFa) to both the
C1R parental and C1R.B*15:02 APC in either the presence or
absence of CBZ (data not shown). Dissection of the individualFrontiers in Immunology | www.frontiersin.org 6CD8+ T cell responses profiled either by single or dual expression
of IFNg and TNF demonstrated significantly higher responses
were driven by IFNg production (p-value <0.05; Mann-Whitney
test; Figure 1B). As expected, the drug-tolerant case did not
respond to CBZ (red dot; Figure 1B).
Priming of Drug-Naïve HLA-B*15:02+
Individuals Required Multiple Rounds of
Drug Exposure
To demonstrate both the kinetics and magnitude of T cell
activation following drug exposure we in vitro stimulated
HLA-B*15:02+ drug-naïve PBMCs (n=7; Table 1) with either
CBZ or its metabolite ECBZ at 25 mg/mL. On days 13 and 27,
outgrown T cells were restimulated with drug (as per day 0) for
continued in vitro expansion. Drug-induced T cell lines were
tested prior to each restimulation and at day 40 (3 intervals total:
day 13, 27 and 40) in a 6-hour ICS assay with either no drug
(untreated), drug (CBZ or ECBZ; 25 mg/mL), or using
C1R.B*15:02 or C1R.B*15:02+drug (CBZ or ECBZ; 25 mg/mL)
as APC with activation quantitated by either IFNg and/or TNF
production. For CBZ-induced T cells, we observed similar
findings to resolved cases (Figure 1) but with delayed kinetics
as drug-specificity predominantly mediated by CD8+ T cells that
was more pronounced by day 40 (Figure 2A). For ECBZ-
induced T cells, the greatest magnitude of immune recognition
was 2.7-fold lower than the CBZ parent drug on day 40 for IFNg
producing cells (C1R.B*15:02+drug; mean ± SEM: 14.28% ± 4.6
for CBZ and 5.16% ± 1.1 for ECBZ; p=0.0029 multiple
comparisons using Holm-Sidak method) (Figure 2B).
Although not all healthy donors demonstrated ECBZ-reactive
CD8+ T cell responses. No drug-induced immunogenicity was
shown by CD4+ T cells, with T-T presentation of CBZ or ECBZ
resulting in minor responses (Figures 2A, B). Examination of
individual data for CBZ-induced CD8+ IFNg+ T cells showed
strong responsiveness for both AP026 (21.5%) and AP029
(33.7%) on day 27 that equated to a 41.4-fold and 48.1-fold
increase, respectively, over the APC background control (i.e.
C1R.B*15:02 vs C1R.B*15:02+CBZ). This net effect was also
demonstrated on day 40 for AP022 (25.4%), AP026 (34.2%)
and AP029 (19.5%) with 14.1-fold, 72.9-fold and 17.3-fold
increases, respectively (Figure 2C). Interestingly, the same level
of in vitro expansion was not observed with the ECBZ
metabolite, with only moderate CD8+IFNg+ T cell responses
measured (5-10% of total CD8+ T cells) on days 27 and 40, with
high APC control background on day 40 being observed across
all individuals (Figure 2D).
CBZ-Reactive T Cell Cross-Reactivity
Towards Tricyclic Aromatics
A previous study examining active cases of HLA-B*15:02-
positive SJS (and one SJS/TEN) and CBZ-tolerant controls
showed CBZ-induced CD8+ T cell cross-reactivity towards
other tricyclic aromatic compounds (21). We wanted to
determine whether T cell cross-reactivity can be achieved
following reactivation of drug-induced T cells in our cohort
of resolved HLA-B*15:02-positive SJS or TEN patients and aApril 2021 | Volume 12 | Article 653710
Mifsud et al. CBZ-Induced TCR and Peptide Repertoiresdrug-tolerant control, where PBMCs were collected between 3-
to-20 years post-reaction (Table 1). Here, in vitro expanded
CBZ-induced T cell lines (generated for Figure 1) were
restimulated in a 6-hour ICS assay with media alone
(untreated), CBZ (25 mg/mL) or C1R.B*15:02 APCs in the
absence or presence of drug (CBZ, ECBZ, OXC, PHT; 25 mg/
mL) and T cell activation measured via IFNg production, with
statistical significance only observed between untreated and
C1R.B*15:02+CBZ (p=0.111, one-way ANOVA with post-hoc
Tukey’s multiple comparison test). We show that CD8+ T cells
primed against the parent drug CBZ can cross-react towards
other ASMs following restimulation with C1R.B*15:02+drug. As
expected, restimulation in the presence of CBZ+APC generated
the highest reactivity (mean ± SEM; 6.771 ± 2.220), followed by
cross-reactivity towards OXC (3.014 ± 0.831) and ECBZ (2.943 ±Frontiers in Immunology | www.frontiersin.org 70.496) (Figures 3A, B). Whilst, minimal CD8+ T cell cross-
reactivity was observed towards the aromatic drug PHT (1.657 ±
0.561), reflecting the more chemically diverse structure of PHT
compared to the other more closely related compounds to CBZ
(Figure 3C).
CD8+ T Cells That Respond to CBZ Exhibit
a High Degree of TCR Clonality
To evaluate whether the TCR repertoire of activated CD8+ T cells
was remodeled following CBZ culture, we analyzed in vitro
expanded HLA-B*15:02-positive PBMCs from two drug-naïve
donors (AP022, AP026), five CBZ-induced SJS cases (T00016,
T00024, E10076, E10314, E10630) and one CBZ-induced TEN
case (E10056) (Table 1). CBZ-reactive T cell lines established
from each individual were restimulated for 4-hours withA
B
FIGURE 1 | Restimulation of drug-reactive memory cells in recovered CBZ-induced SJS and TEN patients is restricted to CD8+ T cells. PBMCs were co-cultured in
the presence of 25 mg/mL CBZ for 14 days. T cell subset phenotype (CD4+ or CD8+) and activation status (production of either IFNg and/or TNFa) were measured
following a 6-hour restimulation with either no drug (untreated), CBZ (25 mg/mL), C1R.B*15:02 or C1R.B*15:02+CBZ (25 mg/mL). Data was acquired on LSRII flow
cytometer (BD) and analyzed using FlowJo software (version 10, BD). All data is expressed as mean ± SEM. (A) Grouped data demonstrated a drug-reactive
response in CD8+ T cells expressing the different combinations of proinflammatory cytokines, but this was not observed for CD4+ T cells (n=7, single data).
(B) Individual data (B*15:02 positive SJS or TEN ([n=6, solid black dots] and Tolerant [n=1, red dot], B*15:02 negative SJS [n=1, open black dot], single data)
showed that activated CD8+ T cell produced significantly more IFNg than TNFa (p-value <0.05; Mann-Whitney test; B).April 2021 | Volume 12 | Article 653710
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FIGURE 2 | Time course of in vitro priming of drug-naïve HLA-B*15:02+ individuals. PBMCs derived from drug-naïve individuals were co-cultured in the presence of
either 25 mg/mL CBZ or ECBZ for 13 to 40 days, with drug restimulation on days 13 and 27. T cell subset phenotype (CD4+ or CD8+) and activation status
(production of either IFNg and/or TNFa) were measured following a 6-hour restimulation with either no drug (untreated), drug (25 mg/mL; CBZ or ECBZ),
C1R.B*15:02 or C1R.B*15:02+drug (25 mg/mL; CBZ or ECBZ). Data was acquired on LSRII flow cytometer (BD) and analyzed using FlowJo software (version 10,
BD). All data is expressed as mean ± SEM. Grouped data demonstrated drug-reactive responses were restricted to CD8+ T cells expressing the different
combinations of proinflammatory cytokines when primed with either (A) CBZ or (B) ECBZ (n=7, single data). Individual data tracking of immune reactivity to drugs
demonstrated that multiple rounds of exposure with either (C) CBZ or (D) ECBZ were required for activation of CD8+ IFNg+ T cells.Frontiers in Immunology | www.frontiersin.org April 2021 | Volume 12 | Article 6537108
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of CBZ (treated, 25 mg/mL), with activated T cells detected by
IFNg secretion. T cells were segregated based on phenotype and
activation status (non-activated: CD8+IFNg- or activated:
CD8+IFNg+), then single cell sorted for subsequent abTCR
repertoire analysis (Supplementary Figure 2C). Profiling of
the activated CBZ-reactive CD8+ TCRs revealed a single major
clonotype observed for the majority of individuals; AP022
(TRAV12-3/TRBV5-5; n=9/23 pairs), AP026 (TRAV26-1/
TRBV27; 16/16), T00024 (TRAV4/TRBV3-1or3-2; 6/23),
E10056 (TRAV21/TRBV30; 8/12) and E10630 (TRAV1-2/
TRBV27; 18/24). Interestingly, AP026 and E10630 share the
same TRBV27 usage (Figure 4, Table 2). Whilst, two major
clonotypes were detected for T00016 (TRAV1-1/TRBV14; 4/23
and TRAV8-2 or 8-4/TRBV15; 4/23) and no clonality was
demonstrated for E10076 or E10314 (HLA-B*15:02-negative
donor). All TCR sequencing information is listed inFrontiers in Immunology | www.frontiersin.org 9Supplementary Table 2. We selected three CBZ-reactive CD8+
TCRs for further functional validation to understand antigen
processing requirements for T cell stimulation (Figure 4,
Table 2).Clonotypic TCRs Exhibit Cross-Reactivity
Towards CBZ Metabolites and Related
ASMs
Retroviral transduction of selected CBZ-reactive CD8+ TCRs
into the SKW3 reporter cell line enabled us to conduct cellular
investigations of TCR recognition to confirm drug specificity
without confounding background T-T presentation (SKW3
reporter cell lines are HLA-B15-negative). Here, TCR
activation was determined by cell surface upregulation of
CD69, with the shift in geometric MFI being measured by flow
cytometry (Figure 5A). We next explored whether HLAA
B
C
FIGURE 3 | CBZ-reactive T cell cross-reactivity towards structures comprising a tricyclic ring. Day 14 CBZ-induced T cell lines derived from SJS and TEN patients
(from Figure 1) were restimulated in a 6-hour ICS assay with media alone (untreated), CBZ (25 mg/mL) or C1R.B*15:02 APCs in the absence or presence of drug
(25 mg/mL; CBZ, ECBZ, OXC, PHT) to measure CD8+ T cell activation via IFNg production. Data was acquired on LSRII flow cytometer (BD) and analyzed using
FlowJo software (version 10, BD). (A) Representative flow cytometric data for SJS patient E10630. (B) Matrix of CBZ-reactive T cell cross-reactivity towards ASMs
with either bicyclic or tricyclic rings in CBZ-reactive patients (single data). (C) Chemical structures of ASMs and the ECBZ metabolite.April 2021 | Volume 12 | Article 653710
Mifsud et al. CBZ-Induced TCR and Peptide Repertoiresallotypes associated with SJS/TEN risk (HLA-B*15:02, B*15:21;
members of B75 serological subgroup) or non-risk (B*15:01,
B*15:25; members of B62 serological subgroup) were able to
stimulate CBZ-reactive TCRs in the presence of drug. A control
APC presenting an irrelevant viral peptide (C1R.B*08:01/FLR)
was also included. For SKW3.AP026, the greatest responses were
observed for CBZ, ECBZ and OXC in the presence of
C1R.B*15:02-positive cells. However, there does appear to be
evidence of non-specific TCR drug-induced responsiveness
across all HLA-B15 allotypes, as well as the HLA-B*08:01Frontiers in Immunology | www.frontiersin.org 10control (Figure 5B, top panel). For SKW3.E10056, TCR
recognition was highly restricted to HLA risk allotypes B*15:02
and B*15:21 and almost exclusively directed against the CBZ
parent drug, with a small response shown for ECBZ in the
presence of C1R.B*15:02 cells. Whilst for SKW3.E10630, the
patterns observed for TCR recognition indicate a high degree of
promiscuity towards risk and non-risk HLA-B15 allotypes across
all drugs. Additionally, the hierarchy of drug recognition was
altered by the presenting allotype, with risk allotype (HLA-
B*15:02/B*15:21) mediated responses being highest forFIGURE 4 | CBZ exposure drives TCR clonality. Representative Circos plots for drug-naïve individual (AP026) and resolved SJS (E10630) and TEN
(E10056) patients showing dominant abTCR clonotype pairings for both CD8+ IFNg- and CD8+ IFNg+ T cell subsets. Circos plots were generated using
an on-line feature based on concatenated pairings of TCRAVJ-CDR3A and TCRBVJ-CDR3B (46). Complete TCR sequencing is shown in
Supplementary Table 2.TABLE 2 | abTCR profiling of CBZ-reactive CD8+ T cells.
ID Drug Reaction TRAV TRAJ CDR3a TRBV TRBJ CDR3b Pair frequency (n)
AP026 Naïve 26-1 26 CIVRSLRDNYGQNFVF 27 1-1 CASRAGGNTEAFF 16/16
E10056 TEN 21 12 CAAKDGMDSSYKLIF 30 1-2 CAWLGAGKVDGYTF 8/12
E10630 SJS 1-2 20 CAAFGDYKLSF 27 2-3 CASSSLSGGWPDTQYF 18/24April 2021 | Volume 12 | Article 653710
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FIGURE 5 | HLA-B*15:02-restricted CBZ-reactive TCRs recognize other drug-exposed HLA-B15 allomorphs. (A) CD69 upregulation assay and flow cytometric
gating strategy to measure activated SKW3.TCR transfectants. Representative data shown from SKW3.E10630, with cell surface CD69 measured as geometric
mean fluorescence intensity (MFI). (B) CBZ-reactive TCR lines (SKW3.AP026, SKW3.E10056, SKW3.E10630) and an EBV-specific irrelevant control (SKW3.LC13)
were stimulated with APCs expressing different HLA-B15 allomorphs in the presence of tricyclic aromatic compounds, and the control C1R.B*08:01 presenting an
irrelevant viral peptide (C1R.B*08:01+FLR) for 17-20 hours. Cells were then stained and data was acquired by flow cytometry (triplicate data, mean ± SEM). (C) Drug
dose response titrations (3.125 to 25 mg/mL) were performed for each HLA-B15 allomorph prior to stimulation of CBZ-reactive TCR lines (SKW3.AP026,
SKW3.E10056, SKW3.E10630) (duplicate data, mean ± SEM).Frontiers in Immunology | www.frontiersin.org April 2021 | Volume 12 | Article 65371011
Mifsud et al. CBZ-Induced TCR and Peptide RepertoiresCBZ>OXC>ECBZ, whilst non-risk allotype (HLA-B*15:01/
B*15:25) mediated responses showed an alternate hierarchy of
CBZ>ECBZ>OXC. As expected, no SKW3.E10056 and
SKW3.E10630 TCR activation towards the irrelevant control
(C1R.B*08:01/FLR) was observed (Figure 5B, middle panels).
Notably, none of the TCRs examined displayed responses to any
of the drugs in the presence of the parental C1R cell line, which
lacks HLA-A and -B expression. An irrelevant TCR control,
SKW3.LC13, was also examined to demonstrate TCR specific
recognition of C1R.B*08:01/FLR and non-activation by drug in
the presence of C1R.B*08:01 or C1R.B*15:02 APCs (Figure 5B,
lower panel).
To determine whether TCR recognition of the non-risk HLA
allotype B*15:01 was drug dose dependent, the drug was titrated
4-fold from 25 mg/mL down to 3.125 mg/mL in the presence of
APCs. For both SKW3.AP026 and SKW3.E10630, as anticipated
TCR activation reduced in accordance with decreasing
concentrations of drug. However, this effect was comparable in
both the risk and non-risk HLA allotypes, B*15:02 and B*15:01,
respectively. Whilst SKW3.E0056 showed remarkable specificity
and sensitivity towards CBZ and decreasing responses towards
the less immunogenic ECBZ, but only when presented by
B*15:02-expressing APC (Figure 5C).
SKW3.TCR Reporter Cells Are Activated
via a Non-Covalent Drug Interaction
We explored whether the SKW3.TCR cells were activated by the
same non-covalent drug interactions as observed for in vitro
expanded CBZ-induced T cell lines. Here, we tested the TCR
transduced reporter cells capacity for activation when both
C1R.B*15:02 and drug were present throughout the assay
(drug addition), as well as when C1R.B*15:02 was pulsed
overnight with drug and then washed prior to co-incubation.
Both SKW3.AP026 (drug-naïve healthy control) and
SKW3.E10630 (SJS patient) cell lines showed a significant
decrease in TCR activation for C1R.B*15:02 drug-pulsed,
compared to C1R.B*15:02 drug addition, across all three drugs
tested (CBZ, ECBZ, OXC; p<0.0001 ANOVA with Tukey
correction) (Figure 6A). These observations mirrored T cell
line data (Figures 1B, 2A) demonstrating a labile drug-HLA-
B*15 interaction in keeping with non-covalent binding.
SKW3.TCR Reporter Cells Do Not Require
Intracellular Antigen Processing for
Activation
We measured whether active antigen processing in APCs for de
novo generation of peptide/HLA complexes was required for
SKW3.TCR activation. Following fixation of C1R.B*15:02 with
1% paraformaldehyde, TCR activation was significantly reduced,
compared to non-fixed C1R.B*15:02, but a notable drug-specific
response was still observed for all three SKW3.TCR cell lines
(Figure 6B, p<0.0001 ANOVA with Tukey correction). These
data align with the nature of interaction between TCR/drug/HLA
molecule not requiring active antigen processing pathways.
Finally, we investigated whether the drug itself binds stably to
the TCR. Here SKW3.E10056 and SKW3.E10630 cells were
either untreated or pulsed with drug (and washed to removeFrontiers in Immunology | www.frontiersin.org 12unbound drug) prior to stimulation with C1R.B*15:02 in either
the absence or presence of drug. Here, maximal TCR activation
was only observed when TCR/drug/C1R.B*15:02 were present
throughout the assay. Thus, potential TCR/drug interactions
alone were assumed to lack the stability to be maintained
without either maintenance of the drug in solution or
stabilization by the HLA present on APC (Figure 6C,
p<0.0001 and p<0.005 ANOVA with Tukey correction).
Minimal Impact of CBZ/ECBZ/OXC on
Peptide Binding Specificity of HLA-B*15:02
Previous analyses of the ligandome of HLA-B*15:02 from CBZ
treated cells have observed co-purification of CBZ (22, 47).
Furthermore, we previously described a minor alteration of the
immunopeptidome reflected in conservation of anchor residue
biases (P2, P9) of co-purified peptides, and modulation of
residues across non-anchor positions. This earlier observation
led us to postulate drug binding at a central position in the
antigen-binding cleft (22). In contrast the metabolite ECBZ has
been suggested to alter peptide binding to soluble HLA-B*15:02,
through interaction in the region of the F-pocket (23). Given the
responses of CBZ-reactive T cells to CBZ, ECBZ and OXC we
sought to determine whether we could define common changes
in peptide binding induced by these three small molecules that
might shed light on the interaction. As previously, we utilized the
C1R.B*15:02 cell line due to its demonstrated ability to present
these molecules in an immunogenic fashion (Figures 5, 6).
Membrane-bound HLA molecules were extracted from 0.9-1.1
x 109 cells through non-denaturing lysis and immunoaffinity
purification, prior to acid elution of peptides, fractionation by
RP-HPLC and LC-MS/MS analysis. Experiments were
performed in duplicate for each of untreated and CBZ treated
(25 mg/mL) cells, whilst single experiments for ECBZ and OXC
treatment (25 mg/mL) conditions were performed to determine if
ECBZ and OXC recapitulated observations for CBZ treatment.
As CBZ, ECBZ and OXC were observed to have distinct
chromatographic retention times during RP-HPLC, aligned with
fraction pools 10 (CBZ), 12 (ECBZ) and 13 (OXC), these specific
pools were also analyzed by multiple reaction monitoring
(MRM) to determine whether drug had co-purified with the
HLA-B*15:02 during immunoaffinity purification. As
anticipated, clear signal for CBZ was observed in pool 10 for
CBZ treated samples at 36 minutes, for ECBZ in pool 12 of ECBZ
treated samples at 28 minutes, and for OXC in pool 13 for OXC
treated samples at 30 minutes (Supplementary Figure 3).
Despite identical masses and monitored transitions, OXC and
ECBZ are distinguished by distinct retention times and transition
hierarchies (Supplementary Figure 3B vs 3C). In the ECBZ
sample, a second peak was also observed at 21 minutes
(Supplementary Figure 3B). Evolution of this second, earlier,
peak was also seen over increased time in the autosampler for
ECBZ prepared as a comparator. Subsequent analysis suggested
that ECBZ is unstable over time in the loading conditions used
for LC-MS analysis (2% ACN, 0.1% FA), with an increase in
signal for a mass consistent with the hydrolysis product (10,11-
dihydroxycarbamazepine, m/z = 271.1+) co-eluting with the
earlier peak (data not shown). It is therefore hypothesized thatApril 2021 | Volume 12 | Article 653710
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which undergoes dehydration during electrospray ionization to
regenerate ECBZ.
Analysis of the eluted peptides identified more than 9900
peptides of 7-20 residues per data set (Figure 7A) as described in
the Materials and Methods. Over 24,000 peptides were identified
in total, with more than 7,000 peptides identified in all
treatments (Figure 7B). Peptides were predominantly 9 amino
acids in length, which were heavily biased towards Leu
(~30%)>Val (~16%)>Gln (~14%) at position 2 of the peptide,
and Tyr (~48%)>Phe (~24%)>Met (~15%)>Leu (~10%) at
position 9 (Figure 7C). Proline was observed at P4 and P5 in
approximately 12% and 10% of peptides respectively, whilst Ser,
Thr and Val were often seen in positions 5-8 of the peptide
(Figure 7C). Only minor differences in amino acid prevalenceFrontiers in Immunology | www.frontiersin.org 13were observed between individual treatments and the untreated
control, and no common perturbation of residue preference was
noted for the three molecules when considering the global
immunopeptidome as might be expected from their cross-
reactivity (Supplementary Figure 4). Due to previous reports
of increased prevalence of deamidated peptides bound to HLA-
B*15:02 after treatment with ECBZ, particularly at P4 (23), we
considered deamidated Asn and Gln separately from their native
form in motif analysis. However, deamidated peptides were
observed to be rare in our analysis (Supplementary Figure 5).
We previously observed minor perturbations of non-anchor
residues when considering peptides uniquely identified in
HLA-I purifications of CBZ treated C1R.B*15:02 as compared
to untreated cells, in analyses based on a smaller dataset (<2000
peptides/condition) (22). The current analysis incorporates moreA
B C
FIGURE 6 | Features of SKW3.TCR activation. (A) CBZ-reactive TCR lines (SKW3.AP026, SKW3.E10630) were stimulated for 17-20 hours with C1R.B*15:02 either
in the presence of drug throughout the assay (drug addition) or drug-pulsed overnight and then washed. Cells were then stained and data was acquired by flow
cytometry (triplicate data, mean ± SEM). A significant decrease was observed when SKW3.TCR cells were stimulated with drug-pulsed C1R.B*15:02 (****p<0.0001;
ANOVA with Tukey correction). (B) SKW3.TCR cells (AP026, E10056, E10630) were stimulated with either untreated or fixed C1R.B*15:02 for 17-20 hours. Cells
were then stained and data was acquired by flow cytometry (triplicate data, mean ± SEM). Whilst a significant reduction in TCR activation was shown, a drug-
reactive response was still observed (****p<0.0001; ANOVA with Tukey correction). (C) SKW3.E10056 and SKW3.E10630 cells were either untreated or pulsed with
drug prior to stimulation with C1R.B*15:02 ± drug. TCR/drug interactions alone were unable to induce CD69 upregulation (****p<0.0001 and **p<0.005; ANOVA with
Tukey correction).April 2021 | Volume 12 | Article 653710
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FIGURE 7 | Binding specificity of HLA-B*15:02 is not overtly perturbed by CBZ, ECBZ or OXC. C1R.B*15:02 were cultured for 48 hours in the presence of 25 mg/
mL CBZ, ECBZ or OXC, or without drug. HLA class I molecules were isolated by immunoaffinity purification and the bound peptides/drugs eluted and analyzed by
LC-MS/MS to characterize the HLA-B*15:02 immunopeptidome under these conditions. Experiments were performed in duplicate for untreated and CBZ treatment
conditions, and single experiments were performed for ECBZ and OXC treatment conditions. (A) Shows the length distribution of peptides identified in each
condition with points representing the number of peptides in individual data sets, and bars representing the mean number of the peptides from duplicate
experiments. (B) To identify the similarity between the conditions, peptides identified in duplicate experiments were combined and the number of peptides
overlapping between the conditions depicted as an upset plot. Points below the graph depict the conditions to which the peptides are common. (C) The proportion
of 9mers in each condition (mean for duplicate experiments) possessing a given amino acid at P1-P9 are depicted as heat maps. Individual scale bars are provided
per position. Amino acids are shown using the single letter code, with the addition of dQ and dN [representing deamidated Gln(Q) and Asn(N)], and cC (representing
Cysteinylation at Cys).Frontiers in Immunology | www.frontiersin.org April 2021 | Volume 12 | Article 65371014
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and more than 18,000 peptides (>11,000 nonamers) per
untreated and CBZ treated conditions when replicates are
combined. We therefore again determined the peptides that
were common (identified in at least 1 replicate of each
condition) and unique (identified in at least 1 replicate of the
condition, but never in the compared condition). We identified
more than 14,000 peptides (>9000 nonamers) common to
untreated and CBZ treatment conditions, with 4246 (2126
nonamers) and 3871 (2129 nonamers) peptides identified in
untreated only (untreated unique) and CBZ treatment only (CBZ
unique), respectively. Focusing on the nonamer peptides, as
anticipated we saw similar anchor preferences to the whole
data set analysis. As observed previously, there were some
variations across the backbone of the peptide (Supplementary
Figures 6), but few were recapitulated in similar analyses of
ECBZ and OXC compared to untreated cells (Supplementary
Figures 7, 8), and overall only 2738 (1211 nonamers) were only
identified in the untreated condition (when compared to all drug
treatment conditions) (Figure 7B). It is therefore difficult to
discern a compelling common drug induced motif across the
three treatments, although a slight reduction in acidic residues at
P1 and tyrosine at P3 were commonly observed (Supplementary
Figures 6–8), as noted previously for CBZ (22). A subtle increase
in Pro at P2 was also observed in peptides uniquely identified in
drug treatments, although Leu remained the dominant
anchor residue.DISCUSSION
Adaptive immune recognition of a foreign entity by T cells relies
on two signals; (1) interaction between an immunogenic antigen/
HLA complex and the TCR and (2) co-stimulation provided by
engagement of B7 (i.e. CD80/CD86) on APCs and CD28
expressed on T cells. The ensuing response drives expansion
and proliferation of T cells containing an armory of effector
functions, including pro-inflammatory cytokine production and
release of cytotoxic molecules, that eliminate pathogen‐infected
or neoplastic cells. Once the elimination process is completed,
attrition of effector T cells leads to the establishment of a memory
T cell pool to combat secondary encounters with the same
immunogenic antigen/HLA complex which lacks the necessity
for signal 2 to allow rapid deployment. Whilst T cell-mediated
immune responses are critical in controlling initial and
subsequent challenges, responses against innocuous stimuli
sometimes occur and are associated with autoimmunity and
allergy, including DHRs.
The impacts of ASM-induced T cell-mediated DHRs have
been well reported [comprehensively reviewed (6, 48)]. Key
insights have been drawn from investigation of three main
cohorts; ASM-induced DHRs [spanning mild (MPE), moderate
(DRESS) and severe (SJS and/or TEN) cases], drug tolerant
patients and drug-naïve healthy donors. Comparison between
these cohorts has provided critical information regarding the
culprit ASM (e.g. CBZ, OXC, PHT, lamotrigine) as well as theFrontiers in Immunology | www.frontiersin.org 15association of HLA allotype (e.g. B*15:02, A*31:01) and ethnicity
(e.g. Han Chinese ancestry) on DHR outcomes. Importantly,
immunopathological examinations during the active phase of the
hypersensitivity reaction has demonstrated a dominant role for
CD8+ T cells and the involvement of key cytolytic (e.g.
granulysin, perforin, granzyme) and proinflammatory
cytokines (e.g. IFNg, macrophage inflammatory protein-1a)
(21, 28, 31, 49–52).
In this study, we examined long-lived T cell reactivity profiles
of resolved CBZ-induced SJS (and one TEN) patients, ranging
from 3 to 20 years post-active disease. In particular, we were
interested in determining whether CBZ-reactive memory T cells
activated upon re-exposure to drug showed similar profiles to
those reported in active disease, considering effector functions,
TCR repertoire clonality, mode of drug recognition and cross-
reactivity towards other ASMs.
CBZ-reactive T cells derived from SJS or TEN patient PBMCs
were expanded for 2 weeks in vitro following a single round of
CBZ exposure. The outgrown bulk T cell culture was then
restimulated with drug either in the absence or presence of an
HLA-B*15:02-expressing APC, and immunophenotypic
properties of CBZ-reactive effector T cells measured by flow
cytometry. We showed that these restimulated T cells were
primarily restricted to the CD8+ T cell lineage and were
capable of Th1 pro-inflammatory cytokine production (IFNg >
TNF), aligning with reported studies of SJS/TEN patients during
active disease (21, 28). For drug-naïve healthy donors, 2-3
rounds of drug exposure (CBZ or ECBZ) were required for in
vitro priming and expansion of drug-reactive T cells. Whilst,
CBZ- and ECBZ-reactive CD8+ T cells were observed by day 40
in all individuals, the ECBZ metabolite had lower levels of
immune responsiveness (with IFNg > TNF) compared to the
parent drug, CBZ.
A common complication of prescribed ASMs is that
individuals who have experienced a DHR are at higher risk of
developing the same, if not, a more severe form of DHR with an
alternate ASM. Indeed, structural similarities exhibited by
aromatic ASMs (i.e. CBZ, OXC, PHT, lamotrigine) provide a
framework for cross-reactive T cell recognition that perpetuates
secondary reactions in between 13-80% of DHR patients (53–
56). This observation is supported by cellular investigations in
SJS/TEN patients with CBZ-induced T cells (generated following
4-5 rounds of in vitro culture) exhibiting cross-reactivity towards
other aromatic compounds such as ECBZ, OXC, lamotrigine and
eslicarbazepine (21). Whilst, non-aromatic ASMs (i.e. valproic
acid and gabapentin) are not generally associated with DHRs
(57). In this study, we demonstrated that CBZ-reactive T cells
(generated following a single in vitro drug exposure) cross-react
with HLA-B*15:02+ APCs in the presence of aromatic ASMs
ECBZ and OXC. The majority of patients showed higher levels of
cross-reactivity towards the ECBZ metabolite, albeit one
individual (E10630) demonstrated greater reactivity towards
OXC. These data suggest an immune hierarchy of T cell cross-
reactivity towards ASMs is likely driven by the common tricyclic
ring structure between CBZ, ECBZ and OXC, but modulated by
different side groups. These observations demonstrate thatApril 2021 | Volume 12 | Article 653710
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vigorously respond to alternate aromatic ASMs, and that T cell
immune monitoring should be undertaken when considering
different treatment options.
We next examined the HLA-B*15:02-restricted TCR
repertoire of CBZ-reactive CD8+ T cells in two drug-naïve
individuals and six SJS or TEN patients. In most cases, a single
major TCR clonotype was observed, which supports previous
findings of focused TCR usage in SJS/TEN patients (28).
However, most of these TCR repertoires showcased private
specificities, with only two individuals (AP026 and E10630)
sharing the same TRBV27 usage, but lacking common CDR3
regions. These findings diverge from previous reports of a more
public TCR usage within the HLA-B*15:02-restricted CBZ-
induced TCR repertoire in SJS and/or TEN patients; that
exhibited dominant Va and Vb clonotypes (28) and a public
abTCR CDR3 sequence (24). Differences in TCR repertoire may
also be attributed to either the site of origin for CBZ-reactive T
cells [i.e. blister fluid/cells vs PBMCs [this study)] and/or
collection of biospecimens during active or resolved (this
study) disease states. It is also important to acknowledge
reported biases associated with the in vitro expansion of T cell
lines (29, 58), with the likelihood of different TCR clonotypes
being expressed by drug-naïve and drug-experienced individuals,
as well as their localization at different sites of pathology (i.e.
blister fluid vs PBMCs). In particular, the study by Pan et al. (24)
could not recapitulate TCR clonotype findings reported by Ko
et al. (28) in the PBMC and blister fluid of SJS/TEN patients.
Although, we have previously shown in anti-viral TCRs that a
bias was not induced between ex vivo PBMCs and day 14 in vitro
T cell cultures (59).
Limited patient biospecimen availability makes it difficult to
conduct a multitude of cellular assays, even with in vitro expansion
of T cell lines and clones. Here we take advantage of a known
reporter system utilizing abTCR deficient SKW3 cells (41, 60) to
examine drug-induced HLA-restricted T cell promiscuity and the
mode of drug presentation. Single major TCR clonotypes, for one
drug-naïve individual (AP026) and two patients (E10056,
E10630), were cloned into the SKW3 reporter cell line. Firstly,
we investigated whether these TCRs demonstrated HLA-B15
specificity towards SJS or TEN risk (B75 subgroup) and non-
risk (B62 subgroup) allotypes (21). Interestingly, we observed
highly restricted TCR recognition for E10056 towards B75
subgroup members B*15:02 and B*15:21, whilst both AP026
and E10630 showed high degree of cross-reactivity towards risk
and non-risk HLA-B*15 allotypes. This observation was apparent
for all HLA-B15 APCs in the presence of CBZ, ECBZ or OXC in a
dose dependent fashion. Furthermore, no responses were observed
in the presence of HLA-B-negative C1R cells. These observations
suggest that non-risk HLA-B15 molecules may also support the
ligation of certain CBZ-reactive TCRs, implying the association of
SJS or TEN with HLA-B*15:02, but not HLA-B*15:01, is not as
simple as the ability of the drug to uniquely interact with one HLA
allomorph but not another.
Secondly, we examined whether ASMs stimulated
SKW3.TCR reporter cells using the same mechanisms requiredFrontiers in Immunology | www.frontiersin.org 16for T cell lines. As observed by others (21, 49, 52), we found it
was essential to maintain soluble drug continuously within the
assay for TCR activation, consistent with a non-covalent and
labile interaction between the drug and peptide/HLA and/or
TCR complex. Additionally, we showed that fixation of APCs did
not abrogate drug-induced TCR activation, which aligns with the
interaction occurring with pre-existing peptide/HLA complexes,
hence not requiring additional antigen processing. Finally, we
showed that TCR/drug interactions were not maintained on
washing of the reporter cells at physiological pH suggesting
any interactions lack sufficient stability to be maintained in the
absence of the peptide/HLA complex. Whilst it has been
suggested that binding can occur directly with a public CBZ-
specific abTCR in the absence of the peptide/HLA complex (24),
we only observed reporter cell activation in the presence of drug
treated HLA-B*15-positive APCs. Hence, the presence of
peptide/HLA, and TCR are necessary for maximal functional
coordination of the drug interaction. Collectively, these data
validate the use of SKW3.TCR reporter cells as an
immunological tool for DHR cellular investigations and
confirm that non-covalent and labile drug/TCR/peptide/HLA
interactions in the absence of new peptide/HLA generation
underpin CBZ-induced DHRs.
In line with the inability of drug pulsed C1R.B*15:02 to
stimulate reporter cell responses, modulation of the
immunopeptidome by CBZ and its derivatives was subtle. This
is distinct from the interaction of abacavir and HLA-B*57:01,
where stable, non-covalent binding within the antigen binding
cleft causes a perturbation of self-peptide presentation, initiated
predominantly in the ER, and alteration of the PΩ anchor
preference of abacavir occupied HLA-B*57:01 molecules (22,
26, 27). We previously observed subtle modulation of non-
anchor residues of peptides bound to HLA-B*15:02 through
comparison of a smaller dataset of HLA-B*15:02 ligands (<2000
peptides per condition). With the current larger dataset (>9900
peptides per condition) and comparison to cross-reactive
molecules ECBZ and OXC not all changes were recapitulated,
although a subtle reduction in acidic amino acids at P1 and
tyrosine at P3 were consistent for peptides unique to drug
treatments (22). This is not to say there are not HLA/peptide/
drug complexes formed but the mechanism for their formation
clearly follows a different trajectory to that of HLA-B*57:01/
abacavir/peptide complexes. Interestingly, our data contrasted a
recent report that ECBZ alters peptide presentation by soluble
HLA-B*15:02 (23). Whether this is due to differences between
soluble and membrane-bound HLA such as reduced interaction
with the peptide loading complex, or the workflow used (e.g. the
necessity for use of detergents to extract membrane-bound HLA,
peptide elution conditions), which might impact complex
stability, remains to be clarified.
As described previously, CBZ and ECBZ were detected in
eluates from affinity purified HLA class I molecules of drug
treated cells (22, 23, 47), an observation that was extended to
OXC. This residual drug is maintained despite washing of the
source cells, as well as the immunoaffinity purified HLA class I
molecules, at physiological pH, a process shown to abrogate APCApril 2021 | Volume 12 | Article 653710
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titration of responses to CBZ, ECBZ and OXC, it is possible
that whilst washing reduces the number of peptide/HLA/drug
complexes below the threshold for activation, some level of
binding is maintained. Regardless, failure to identify a distinct
peptide motif in drug treated cells and the inability of either the
peptide/HLA or TCR alone to maintain sufficient drug
interaction for immunogenicity on removal of soluble drug,
collectively suggest that CBZ and related compounds form a
tripartite interaction with peptide/HLA/TCR. Furthermore,
differences in recognition hierarchies of CBZ, ECBZ and OXC
by the three TCRs investigated suggest the epoxide (ECBZ) and
ketone (OXC) more prominently impact TCR ligation as
opposed to interaction with the HLA, thus may be oriented
towards the TCR.
In conclusion, this study confirms the presence of long-lived
immunological effects in resolved CBZ-induced SJS and TEN
patients, which are characterized by a highly clonal drug-reactive
CD8+ TCR repertoire. Furthermore, using a combination of the
definition of the functional requirements for TCR engagement
using transduced reporter cell lines and detailed study of the
impact of CBZ, ECBZ and OXC on HLA-B*15:02 peptide
presentation, our work supports the hypothesis that peptide/
HLA and TCR are required for drug interactions able to elicit
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Supplementary Figure 1 | HLA staining of Antigen Presenting Cells and
SKW3.TCR expression. C1R Parental and transfected cells expressing different
HLA-B15 allotypes were stained with primary antibodies (A) anti-human pan HLA-I
(W6/32 hybridoma) and (B) anti-human HLA-Bw6 (HB152 hybridoma) followed by
a goat anti-mouse IgG PE secondary antibody. A secondary (2°) antibody alone
control was used for background staining. (C) All four SKW3 cell lines were
periodically tested for TCR cell surface expression. A total of 30,000 cells were
acquired on LSRII flow cytometer (BD) and data was analyzed using FlowJo
software (version 10, BD).
Supplementary Figure 2 | In vitro expansion of CBZ-reactive T cells and cell
sorting for abTCR repertoire analysis. (A) Drug-reactive T cells were outgrown
following 14 days of PBMC stimulation with 25 mg/mL CBZ. Day 14 T cells were
restimulated for 6 hours with C1R cells expressing different HLA-B15 allotypes in
the presence or absence of 25 mg/mL CBZ. T cell phenotype and activation was
then measured by flow cytometry. (B) Gating strategy shown is representative data
from SJS patient E10630. A maximum of 50,000 lymphocytes were acquired on
LSRII flow cytometer (BD) and data was analyzed using FlowJo software (version
10, BD). (C) Day 14 CBZ-reactive T cells were restimulated with C1R.B*15:02 in
either the absence (negative control) or presence of 25 mg/mL CBZ for 4 hours.
Activated CD8+ T cells were detected using an IFNg secretion assay. Single cell
sorting of both CD8+ IFNg- and CD8+ IFNg+ T cell subsets for TCR repertoire
analysis were performed using an Influx flow cytometer (BD).April 2021 | Volume 12 | Article 653710
Mifsud et al. CBZ-Induced TCR and Peptide RepertoiresSupplementary Figure 3 | Drug molecules co-purify with HLA-B*15:02. (A-C)
Show raw intensities for transitions monitoring (A) CBZ in pool 10 of CBZ replicate
1, (B) ECBZ in pool 12 of ECBZ, (C) OXC in pool 13 of OXC. (D-F) summarize the
normalized signal for CBZ (D), ECBZ (separated into the signal at 21 minutes (RT
21) and 28 minutes (RT 28) (E) and OXC (F) in pools 10, 12 and 13, respectively.
Supplementary Figure 4 | Deviations in amino acid prevalence observed
between treatments are minimal. Points represent differences between the amino
acid prevalence at each position for drug/metabolite treatments as compared to the
untreated control (mean of duplicate experiments). For CBZ, points are the
difference of the mean of duplicate data sets with error bars showing standard error
of the difference (calculated using Welch t-test).
Supplementary Figure 5 | No major alteration of the contribution of deamidated
peptides to the HLA-B*15:02 immunopeptidome by drug treatment. Graphs show
the percentage of 9mer peptides annotated as containing native Glutamine (top
left), native Asparagine (top right), deamidated Glutamine (bottom left) and
deamidated asparagine (bottom right) at each position of the peptide. For untreated
and CBZ treatment, values are the mean of two replicate experiments, error bars
show the standard deviation. ECBZ and OXC treatment are singlet values.
Supplementary Figure 6 | Amino acid prevalence for 9mer peptides unique to
CBZ treatment when compared to control conditions. Combined lists of peptides
identified in at least 1 replicate of the control condition (untreated) and CBZ
treatment were generated and compared to generate 3 categories; untreated
unique – identified in at least one replicate of the untreated control, but not in either
replicate of CBZ treatment, common – identified in at least one replicate of the
untreated control and at least one replicate of the CBZ treatment, and CBZ unique –Frontiers in Immunology | www.frontiersin.org 18identified in neither replicate of the untreated control, but in at least one replicate of
CBZ treatment. Bar graphs show the percentage of 9mer peptides possessing a
given amino acid at each position of the peptide per category. n is the number of
9mer peptides in the category. Arrows indicate residues discussed in the text.
Supplementary Figure 7 | Amino acid prevalence for 9mer peptides unique to
ECBZ treatment when compared to control conditions. A combined list of peptides
identified in at least 1 replicate of the control condition (untreated) was generated
and compared to the ECBZ treatment data set to generate 3 categories; untreated
unique – identified in at least one replicate of the untreated control, but not in ECBZ
treatment, common – identified in at least one replicate of the untreated control and
in the ECBZ treatment, and ECBZ unique – identified in neither replicate of the
untreated control, but in ECBZ treatment. Bar graphs show the percentage of 9mer
peptides possessing a given amino acid at each position of the peptide per
category. n is the number of 9mer peptides in the category. Arrows indicate
residues discussed in the text.
Supplementary Figure 8 | Amino acid prevalence for 9mer peptides unique to
OXC treatment when compared to control conditions. A combined list of peptides
identified in at least 1 replicate of the control condition (untreated) was generated
and compared to the OXC treatment data set to generate 3 categories; untreated
unique – identified in at least one replicate of the untreated control, but not in OXC
treatment, common – identified in at least one replicate of the untreated control and
in the OXC treatment, and OXC unique – identified in neither replicate of the
untreated control, but in OXC treatment. Bar graphs show the percentage of 9mer
peptides possessing a given amino acid at each position of the peptide per
category. n is the number of 9mer peptides in the category. Arrows indicate
residues discussed in the text.REFERENCES
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